Base de dados : MEDLINE
Pesquisa : E07.858.499 [Categoria DeCS]
Referências encontradas : 1045 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 105 ir para página                         

  1 / 1045 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29424981
[Au] Autor:Arango-Buitrago V; Restrepo-Moreno M; Echavarría-Restrepo LG; Gómez-Londoño M
[Ti] Título:[Pelvic organ prolapse during pregnancy: treatment with vaginal pessary. A report of two cases].
[Ti] Título:Prolapso de órganos pélvicos durante el embarazo tratado con pesario. Reporte de dos casos..
[So] Source:Ginecol Obstet Mex;84(9):601-6, 2016 Sep.
[Is] ISSN:0300-9041
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:Background: Pelvic organ prolapse during pregnancy is a rare condition that may be associated with maternal and fetal complications. Objetive: To describe the experience of two cases of pelvic organ prolapse during pregnancy managed with vaginal pessary. Case report: The cases of two patients with grade 4 vaginal prolapse during pregnancy managed with vaginal pessary until the time of delivery are presented. The patients had improvement of their symptoms without complications related to prolapse or pessary use. Conclusion: Early recognition, monitoring and management of this condition are essential. The vaginal pessary is a good option for transient treatment and is associated with few complications.
[Mh] Termos MeSH primário: Prolapso de Órgão Pélvico/terapia
Pessários
Complicações na Gravidez/terapia
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Gravidez
Resultado da Gravidez
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  2 / 1045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:29260226
[Au] Autor:Saccone G; Maruotti GM; Giudicepietro A; Martinelli P; Italian Preterm Birth Prevention (IPP) Working Group
[Ad] Endereço:Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.
[Ti] Título:Effect of Cervical Pessary on Spontaneous Preterm Birth in Women With Singleton Pregnancies and Short Cervical Length: A Randomized Clinical Trial.
[So] Source:JAMA;318(23):2317-2324, 2017 12 19.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Spontaneous preterm birth is a major cause of perinatal morbidity and mortality. It is unclear if a cervical pessary can reduce the risk of spontaneous preterm delivery. Objective: To test whether in asymptomatic women with singleton pregnancies and no prior spontaneous preterm birth but with short cervical length on transvaginal ultrasound, use of a cervical pessary would reduce the rate of spontaneous preterm birth at less than 34 weeks of gestation. Design, Setting, and Participants: Parallel-group, nonblinded, randomized clinical trial conducted from March 1, 2016, to May 25, 2017, at a single center in Italy. Asymptomatic women with singleton gestations, no previous spontaneous preterm births, and cervical lengths of 25 mm or less at 18 weeks 0 days to 23 weeks 6 days of gestation were eligible. Interventions: Patients were randomized 1:1 to receive either cervical pessary (n = 150) or no pessary (n = 150). The pessary was removed between 37 weeks 0 days and 37 weeks 6 days of gestation or earlier if clinically indicated. The control group received standard care. For cervical length of 20 mm or shorter, women in both groups were prescribed vaginal progesterone, 200 mg/d, until 36 weeks 6 days of gestation. No bed rest or activity restriction was recommended. Main Outcomes and Measures: The primary end point was spontaneous preterm birth at less than 34 weeks of gestation. Secondary outcomes were adverse events. Results: Among 300 women who were randomized (mean age, 29 [SD, 6.3] years; mean gestational age, 22 [SD, 1.3] weeks), 100% completed the trial. The primary end point occurred in 11 women (7.3%) in the pessary group and 23 women (15.3%) in the control group (between-group difference, -8.0% [95% CI, -15.7% to -0.4]; relative risk, 0.48 [95% CI, 0.24-0.95]). During follow-up, the pessary group had a higher rate of increased or new vaginal discharge (86.7% vs 46.0%; between-group difference, +40.7% [95% CI, +30.1%-+50.3%]; relative risk, 1.88 [95% CI, 1.57-2.27]). Conclusions and Relevance: Among women without prior spontaneous preterm birth who had asymptomatic singleton pregnancies and short transvaginal cervical length, use of a cervical pessary, compared with no pessary use, resulted in a lower rate of spontaneous preterm birth at less than 34 weeks of gestation. The results of this single-center, nonblinded study among selected pregnant women require confirmation in multicenter clinical trials. Trial Registration: clinicaltrials.gov Identifier: NCT02716909.
[Mh] Termos MeSH primário: Colo do Útero/anatomia & histologia
Pessários
Nascimento Prematuro/prevenção & controle
[Mh] Termos MeSH secundário: Administração Intravaginal
Adulto
Medida do Comprimento Cervical
Terapia Combinada
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Gravidez
Progesterona/uso terapêutico
Progestinas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Progestins); 4G7DS2Q64Y (Progesterone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171221
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.18956


  3 / 1045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29260206
[Au] Autor:Silver RM; Branch DW
[Ad] Endereço:Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City.
[Ti] Título:Cervical Pessary to Prevent Preterm Birth.
[So] Source:JAMA;318(23):2299-2300, 2017 12 19.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Pessários
Nascimento Prematuro/prevenção & controle
[Mh] Termos MeSH secundário: Colo do Útero
Feminino
Seres Humanos
Recém-Nascido
Gravidez
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171222
[Lr] Data última revisão:
171222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.18955


  4 / 1045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28748254
[Au] Autor:Hanis SM; Khazaei S; Ayubi E; Mansori K
[Ad] Endereço:Dezful University of Medical Sciences, Dezful, Iran.
[Ti] Título:Comment on: Predictors of unsuccessful pessary fitting in women with prolapse: a cross-sectional study in general practice.
[So] Source:Int Urogynecol J;28(9):1439, 2017 09.
[Is] ISSN:1433-3023
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Prolapso de Órgão Pélvico
Pessários
[Mh] Termos MeSH secundário: Estudos Transversais
Feminino
Medicina Geral
Seres Humanos
Prolapso Uterino
[Pt] Tipo de publicação:LETTER; COMMENT
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.1007/s00192-017-3359-7


  5 / 1045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28748253
[Au] Autor:Dekker JH; Burger H
[Ad] Endereço:Department of General Practice, University Medical Center Groningen, University of Groningen, P.O. Box 196, 9700 AD, Groningen, The Netherlands. j.h.dekker@umcg.nl.
[Ti] Título:Authors' reply to the comment by Hanis et al. on "Predictors of unsuccessful pessary fitting in women with prolapse: a cross-sectional study in general practice," by Panman et al.
[So] Source:Int Urogynecol J;28(9):1441, 2017 09.
[Is] ISSN:1433-3023
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Prolapso de Órgão Pélvico
Pessários
[Mh] Termos MeSH secundário: Estudos Transversais
Feminino
Medicina Geral
Seres Humanos
Prolapso Uterino
[Pt] Tipo de publicação:LETTER; COMMENT
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.1007/s00192-017-3421-5


  6 / 1045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29064971
[Au] Autor:Committee on Practice Bulletins-Gynecology, American Urogynecologic Society
[Ti] Título:Practice Bulletin No. 185: Pelvic Organ Prolapse.
[So] Source:Obstet Gynecol;130(5):e234-e250, 2017 11.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pelvic organ prolapse (POP) is a common, benign condition in women. For many women it can cause vaginal bulge and pressure, voiding dysfunction, defecatory dysfunction, and sexual dysfunction, which may adversely affect qual-ity of life. Women in the United States have a 13% lifetime risk of undergoing surgery for POP (1). Although POP can occur in younger women, the peak incidence of POP symptoms is in women aged 70-79 years (2). Given the aging population in the United States, it is anticipated that by 2050 the number of women experiencing POP will increase by approximately 50% (3). The purpose of this joint document of the American College of Obstetricians and Gynecologists and the American Urogynecologic Society is to review information on the current understanding of POP in women and to outline guidelines for diagnosis and management that are consistent with the best available scientific evidence.
[Mh] Termos MeSH primário: Procedimentos Cirúrgicos em Ginecologia
Prolapso de Órgão Pélvico/terapia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Pessários
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002399


  7 / 1045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28949973
[Au] Autor:Crowther CA; Ashwood P; McPhee AJ; Flenady V; Tran T; Dodd JM; Robinson JS; PROGRESS Study Group
[Ad] Endereço:Liggins Institute, University of Auckland, Auckland, New Zealand.
[Ti] Título:Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial.
[So] Source:PLoS Med;14(9):e1002390, 2017 Sep.
[Is] ISSN:1549-1676
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Neonatal respiratory distress syndrome, as a consequence of preterm birth, is a major cause of early mortality and morbidity. The withdrawal of progesterone, either actual or functional, is thought to be an antecedent to the onset of labour. There remains limited information on clinically relevant health outcomes as to whether vaginal progesterone may be of benefit for pregnant women with a history of a previous preterm birth, who are at high risk of a recurrence. Our primary aim was to assess whether the use of vaginal progesterone pessaries in women with a history of previous spontaneous preterm birth reduced the risk and severity of respiratory distress syndrome in their infants, with secondary aims of examining the effects on other neonatal morbidities and maternal health and assessing the adverse effects of treatment. METHODS: Women with a live singleton or twin pregnancy between 18 to <24 weeks' gestation and a history of prior preterm birth at less than 37 weeks' gestation in the preceding pregnancy, where labour occurred spontaneously or in association with cervical incompetence or following preterm prelabour rupture of the membranes, were eligible. Women were recruited from 39 Australian, New Zealand, and Canadian maternity hospitals and assigned by randomisation to vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone) (n = 398) or placebo (n = 389). Participants and investigators were masked to the treatment allocation. The primary outcome was respiratory distress syndrome and severity. Secondary outcomes were other respiratory morbidities; other adverse neonatal outcomes; adverse outcomes for the woman, especially related to preterm birth; and side effects of progesterone treatment. Data were analysed for all the 787 women (100%) randomised and their 799 infants. FINDINGS: Most women used their allocated study treatment (740 women, 94.0%), with median use similar for both study groups (51.0 days, interquartile range [IQR] 28.0-69.0, in the progesterone group versus 52.0 days, IQR 27.0-76.0, in the placebo group). The incidence of respiratory distress syndrome was similar in both study groups-10.5% (42/402) in the progesterone group and 10.6% (41/388) in the placebo group (adjusted relative risk [RR] 0.98, 95% confidence interval [CI] 0.64-1.49, p = 0.912)-as was the severity of any neonatal respiratory disease (adjusted treatment effect 1.02, 95% CI 0.69-1.53, p = 0.905). No differences were seen between study groups for other respiratory morbidities and adverse infant outcomes, including serious infant composite outcome (155/406 [38.2%] in the progesterone group and 152/393 [38.7%] in the placebo group, adjusted RR 0.98, 95% CI 0.82-1.17, p = 0.798). The proportion of infants born before 37 weeks' gestation was similar in both study groups (148/406 [36.5%] in the progesterone group and 146/393 [37.2%] in the placebo group, adjusted RR 0.97, 95% CI 0.81-1.17, p = 0.765). A similar proportion of women in both study groups had maternal morbidities, especially those related to preterm birth, or experienced side effects of treatment. In 9.9% (39/394) of the women in the progesterone group and 7.3% (28/382) of the women in the placebo group, treatment was stopped because of side effects (adjusted RR 1.35, 95% CI 0.85-2.15, p = 0.204). The main limitation of the study was that almost 9% of the women did not start the medication or forgot to use it 3 or more times a week. CONCLUSIONS: Our results do not support the use of vaginal progesterone pessaries in women with a history of a previous spontaneous preterm birth to reduce the risk of neonatal respiratory distress syndrome or other neonatal and maternal morbidities related to preterm birth. Individual participant data meta-analysis of the relevant trials may identify specific women for whom vaginal progesterone might be of benefit. TRIAL REGISTRATION: Current Clinical Trials ISRCTN20269066.
[Mh] Termos MeSH primário: Pessários
Nascimento Prematuro/prevenção & controle
Progesterona/administração & dosagem
Síndrome do Desconforto Respiratório do Recém-Nascido/prevenção & controle
[Mh] Termos MeSH secundário: Administração Intravaginal
Adulto
Austrália
Canadá
Feminino
Seres Humanos
Recém-Nascido
Nova Zelândia
Placebos
Gravidez
Resultado da Gravidez
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Placebos); 4G7DS2Q64Y (Progesterone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170927
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pmed.1002390


  8 / 1045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28797120
[Au] Autor:Tappa K; Jammalamadaka U; Ballard DH; Bruno T; Israel MR; Vemula H; Meacham JM; Mills DK; Woodard PK; Weisman JA
[Ad] Endereço:Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
[Ti] Título:Medication eluting devices for the field of OBGYN (MEDOBGYN): 3D printed biodegradable hormone eluting constructs, a proof of concept study.
[So] Source:PLoS One;12(8):e0182929, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:3D printing has the potential to deliver personalized implants and devices for obstetric and gynecologic applications. The aim of this study is to engineer customizable and biodegradable 3D printed implant materials that can elute estrogen and/or progesterone. All 3D constructs were printed using polycaprolactone (PCL) biodegradable polymer laden with estrogen or progesterone and were subjected to hormone-release profile studies using ELISA kits. Material thermal properties were tested using thermogravimetric analysis and differential scanning calorimetry. The 3D printed constructs showed extended hormonal release over a one week period. Cytocompatibility and bioactivity were assessed using a luciferase assay. The hormone-laden 3D printed constructs demonstrated an increase in luciferase activity and without any deleterious effects. Thermal properties of the PCL and hormones showed degradation temperatures above that of the temperature used in the additive manufacturing process-suggesting that 3D printing can be achieved below the degradation temperatures of the hormones. Sample constructs in the shape of surgical meshes, subdermal rods, intrauterine devices and pessaries were designed and printed. 3D printing of estrogen and progesterone-eluting constructs was feasible in this proof of concept study. These custom designs have the potential to act as a form of personalized medicine for drug delivery and optimized fit based on patient-specific anatomy.
[Mh] Termos MeSH primário: Implantes Absorvíveis
Materiais Biocompatíveis/química
Sistemas de Liberação de Medicamentos/instrumentação
Estrogênios/administração & dosagem
Poliésteres/química
Progesterona/administração & dosagem
[Mh] Termos MeSH secundário: Desenho de Equipamento
Feminino
Seres Humanos
Dispositivos Intrauterinos Medicados
Pessários
Impressão Tridimensional
Telas Cirúrgicas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Estrogens); 0 (Polyesters); 24980-41-4 (polycaprolactone); 4G7DS2Q64Y (Progesterone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182929


  9 / 1045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28647957
[Au] Autor:Duan L; Lu YX; Shen WJ; Liu X; Liu JX; Zhang YH; Ge J; Zhao Y; Niu K; Wang WY
[Ad] Endereço:Department of Obstetrics and Gynecology, First Affiliated Hospital, General Hospital of People's Liberation Army, Beijing 100048, China.
[Ti] Título:[Long-term effectiveness of transvaginal high uterosacral ligament suspension].
[So] Source:Zhonghua Fu Chan Ke Za Zhi;52(6):363-368, 2017 Jun 25.
[Is] ISSN:0529-567X
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To assess the long-term effectiveness of the transvaginal high uterosacral ligament suspension (HUS) in women suffering from advanced pelvic organ prolapse (POP). A retrospective review of records identified 118 women who underwent transvaginal HUS with or without additional concomitant anterior and (or) posterior repairs from June 2003 to August 2009 in the First Affiliated Hospital, General Hospital of People s Liberation Army. Of 118 women, 104 women completed the follow-up during study period; these 104 women were analysed. Follow-up visits were performed 2, 6 and 12 months after surgery and then annually. Anatomic results of POP was established by pelvic examination using pelvic organ prolapse quantitation system (POP-Q) staging. Funtional results were obtained by patient global impression of improvement (PGI-I), pelvic floor distress inventory-short form 20 (PFDI-20) and pelvic floor impact questionnaire short form (PFIQ-7). Surgical success required the fulfillment of all 3 criteria: (1) prolapse leading edge of 0 cm or less and apex of 1/2 total vaginal length or less; (2) the absence of pelvic organ prolapse symptoms as reported on the PFDI-20 question No. 3 ( "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" ); and (3) no prolapse reoperations or pessary use during the study period. The mean follow-up time was (9.1±1.5) years. The overall surgery success rate was 91.3% (95/104) according to above all 3 criteria. Prolapse recurrence rates were isolated anterior 6.7% (7/104), isolated apical 0, isolated posterior 2.9% (3/104) and multiple compartments 1.0% (1/104). Five women (4.8%, 5/104) developed bothersome vaginal bulge symptoms. None of recurrent women underwent retreatment, including either surgery or use of a pessary at last follow-up. The subjective satisfaction rate was 90.4% (94/104). PFDI-20 and PFIQ-7 scores showed a statistically significant improvement from preoperative 72 and 65 points to postoperative 17 and 9 points respectively (all 0.01). There was a 2.9% (3/104) rate of intraoperative ureteral kinking and 3.8% (4/104) rate of postoperative morbidity. The transvaginal HUS for vault prolapse offers good long-term anatomical results with excellent vault suspension. With additional concomitant anterior and (or) posterior repairs, it will be a reconstructive surgery for the majority of advanced POP. It is minimal traumatic and appropriate for different type of POP, especially for the eldly patients. It is worthy of being popularized for clinical application.
[Mh] Termos MeSH primário: Procedimentos Cirúrgicos em Ginecologia/métodos
Ligamentos/cirurgia
Prolapso de Órgão Pélvico/cirurgia
Vagina/cirurgia
[Mh] Termos MeSH secundário: China/epidemiologia
Feminino
Seres Humanos
Meia-Idade
Diafragma da Pelve/cirurgia
Prolapso de Órgão Pélvico/patologia
Peritônio
Pessários
Complicações Pós-Operatórias/epidemiologia
Período Pós-Operatório
Estudos Retrospectivos
Sacro/cirurgia
Slings Suburetrais
Inquéritos e Questionários
Resultado do Tratamento
Prolapso Uterino
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170627
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-567X.2017.06.002


  10 / 1045 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28594757
[Au] Autor:Taege SK; Adams W; Mueller ER; Brubaker L; Fitzgerald CM; Brincat C
[Ad] Endereço:Departments of Obstetrics & Gynecology and Urology, Loyola University Medical Center, and the Departments of Obstetrics & Gynecology, Urology, and Physical Medicine and Rehabilitation, and the Health Sciences Division, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
[Ti] Título:Anesthetic Cream Use During Office Pessary Removal and Replacement: A Randomized Controlled Trial.
[So] Source:Obstet Gynecol;130(1):190-197, 2017 Jul.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To estimate the effect of lidocaine-prilocaine cream on patient pain at the time of office pessary removal and reinsertion. METHODS: In this double-blind, randomized placebo-controlled trial, participants undergoing routine pessary care in a urogynecology office at a tertiary referral center were randomized to application of 4 g of either lidocaine-prilocaine or placebo cream 5 minutes before pessary change. Visual analog scale pain scores were collected from the patient at baseline, after pessary removal, and after pessary reinsertion. Physicians also recorded their estimate of patient pain at pessary removal and reinsertion. The primary outcome was the participant-reported visual analog scale pain score at the time of pessary removal and reinsertion. A sample size of 26 per group (n=52) was planned to estimate an absolute mean difference in visual analog scale pain of 2.1 cm at the time of pessary removal. An analysis of covariance was used to evaluate pain at removal and reinsertion as a function of treatment assignment controlling for baseline pain. RESULTS: From July 2015 through February 2016, 116 women were screened and 54 were recruited: 28 in the lidocaine-prilocaine cream group and 26 in the placebo group. One patient in the lidocaine-prilocaine cream group was later withdrawn owing to vaginal erosion. The participants were all postmenopausal women, with an average age of 77.8 years. Most characteristics were similar between groups. After adjusting for baseline pain, participants randomized to the lidocaine-prilocaine group had lower pain at pessary removal when compared with those assigned to placebo (mean difference=-2.05, 95% confidence interval -3.69 to -0.41; P=.015). CONCLUSION: Lidocaine-prilocaine cream use at the time of office pessary removal reduces patient-reported pain. Clinicians may wish to include this simple intervention to optimize patient comfort and compliance. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02380742.
[Mh] Termos MeSH primário: Anestésicos Locais/uso terapêutico
Lidocaína/uso terapêutico
Pessários/utilização
Prilocaína/uso terapêutico
[Mh] Termos MeSH secundário: Administração Intravaginal
Idoso
Anestésicos Locais/administração & dosagem
Método Duplo-Cego
Combinação de Medicamentos
Feminino
Seres Humanos
Lidocaína/administração & dosagem
Medição da Dor
Satisfação do Paciente
Prilocaína/administração & dosagem
Resultado do Tratamento
Cremes, Espumas e Géis Vaginais
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anesthetics, Local); 0 (Drug Combinations); 0 (Vaginal Creams, Foams, and Jellies); 046O35D44R (Prilocaine); 98PI200987 (Lidocaine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002098



página 1 de 105 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde